Handa Pharmaceuticals, Inc. (TPEX:6620)
Taiwan · Delayed Price · Currency is TWD 87.60
+0.30 (0.34%)
Jul 29, 2026, 1:30 PM CST
Handa Pharmaceuticals Financials Overview
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 1,758 | 1,729 | 830.67 | 1,106 | 197.68 | 29.24 |
Revenue Growth | 121.39% | 108.17% | -24.92% | 459.66% | 576.16% | 1.30% |
Gross Profit Gross Profit Growth | 1,491 | 1,462 | 829.5 | 1,105 | 178.97 | 27.77 |
Operating Income Operating Income Growth | 952.45 | 934.18 | 418.06 | 693.43 | -88.12 | -253.88 |
Net Income Net Income Growth | 780.8 | 749.77 | 472.74 | 726.89 | -40.01 | -247.67 |
Earnings Per Share EPS Growth | 4.86 | 4.83 | 3.35 | 5.40 | -0.32 | -2.10 |
EPS Growth | 72.63% | 44.18% | -37.96% | - | - | - |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 3,766 | 3,704 | 1,829 | 2,317 | 365.91 | 283.27 |
Total Debt Total Debt Growth | 46 | 47.64 | 40.1 | 13.24 | 29.59 | 11.89 |
Net Cash (Debt) Net Cash Growth | 3,720 | 3,656 | 1,789 | 2,304 | 336.32 | 271.38 |
Net Cash Growth | 107.90% | 104.32% | -22.33% | 584.95% | 23.93% | -10.06% |
Net Cash Per Share Net Cash Per Share Growth | 23.16 | 23.54 | 12.68 | 17.10 | 2.68 | 2.31 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 358.67 | 243.63 | 497.6 | 668.36 | -211.57 | -179.24 |
Capital Expenditures CapEx Growth | -35.18 | -16.92 | -7.77 | -0.94 | -0.64 | -5.58 |
Free Cash Flow Free Cash Flow Growth | 323.49 | 226.72 | 489.84 | 667.42 | -212.21 | -184.82 |
Free Cash Flow Growth | 12.05% | -53.72% | -26.61% | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 84.83% | 84.53% | 99.86% | 99.88% | 90.53% | 95.00% |
Operating Margin | 54.18% | 54.02% | 50.33% | 62.68% | -44.58% | -868.42% |
Pretax Margin | 55.58% | 54.18% | 57.68% | 71.63% | -21.83% | -892.08% |
Profit Margin | 44.41% | 43.36% | 56.91% | 65.70% | -20.24% | -847.17% |
FCF Margin | 18.40% | 13.11% | 58.97% | 60.33% | -107.35% | -632.19% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Dividend Per Share Dividend Per Share Growth | 2.000 | 2.000 | 1.507 | 1.000 |
Dividend Per Share Growth | 37.63% | 32.73% | 50.68% | - |
Dividend Yield | 2.29% | 2.37% | 2.09% | 0.57% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 18.03 | 18.05 | 22.37 | 35.62 | - | - |
Forward PE | 21.47 | 5.59 | 5.59 | 14.69 | - | - |
P/FCF Ratio | 45.10 | 59.68 | 21.59 | 38.79 | - | - |
PS Ratio | 8.30 | 7.82 | 12.73 | 23.40 | 81.32 | 289.08 |